Novelion Therapeutics Inc. reported the election of John Orloff, Mark DiPaolo and Suzanne Bruhn to the company’s board of directors on current reports on Form 8-K filed on June 1, 2017, August 2, 2017 and September 11, 2017, respectively. As part of the board’s annual committee review, the board approved the following standing committee assignments for all directors, effective November 13, 2017: Audit Committee: John C. Thomas Jr. (chair), Mark Corrigan and Stephen L. Sabba. Compensation Committee: Stephen L. Sabba (chair), Suzanne Bruhn and John C. Thomas Jr. Compliance Committee: Donald K. Stern (chair), Jason M. Aryeh and Mark Corrigan. Corporate Governance and Nominating Committee: Kevin Kotler (chair), Jason M. Aryeh and Mark DiPaolo. Scientific and Innovation Committee: John Orloff (chair), Suzanne Bruhn and Mark Corrigan.